Objects: To acquire adequate proximal landing zones for penetrating aortic ulcers in the proximal descending aorta or aortic arch, the left subclavian artery (LSA) is usually covered during thoracic endovascular aortic repair. The Castor single-branched stent graft is used to treat aortic disease involving LSA. Our goal was to evaluate the efficiency and safety of the Castor device in treating penetrating aortic ulcers (PAUs) involving the LSA. METHODS: Between January 2019 and December 2020, we enrolled 25 patients with PAUs requiring LSA revascularization using Castor devices during thoracic endovascular aortic repair (TEVAR). Outcomes including surgical results, 30-day and follow-up deaths and morbidity and aortic computed tomography angiography data were analyzed. RESULTS: In total, 24 patients (96.0%) underwent successful surgical procedures: 1 patient (4.0%) had a type I endoleak and 1 patient (4.0%) had a stroke. Stent migration occurred in 1 patient (4.0%) and paraplegia in 1 patient (4.0%). Two stents were deployed in 2 patients (8.0%). After a mean follow-up period of 15.7 months, 2 cases of branch occlusions and 1 death related to myocardial infarction were noted. Aortic computed tomography angiography demonstrated that the diameters and depths were reduced significantly whereas complete thrombosis of the lumens of the PAUs occurred in all cases during the 12-months follow-up period. CONCLUSIONS: These preliminary results justify the efficiency and safety of the Castor single branched stent graft in the treatment of PAUs requiring LSA revascularization.
12 August 2021 in Journal of Cardiothoracic Surgery
The incidence of bicuspid aortic valves (BAV) is high in the whole population, BAV-related thoracic aortic aneurysm (TAA) is accompanied by many adverse vascular events. So far, there are two key points in dealing with BAV-related TAA. First is fully understanding on its pathogenesis. Second is optimizing surgical intervention time. This review aims to illustrate the potential role of miRNAs in both aspects, that is, how miRNAs are involved in the occurrence and progression of BAV-related TAA, and the feasibilities of miRNAs as biomarkers.
Type A aortic dissection (AD) is a catastrophic cardiovascular disease. Hypoxia‐inducible factor‐1α (HIF‐1α) and autophagy are reported to be upregulated in the AD specimens. However, the interaction between HIF‐1α and autophagy in the pathogenesis of AD remains to be explored. HIF‐1α and LC3 levels are evaluated in 10 AD and 10 normal aortic specimens. MDC staining, autophagic vacuoles, and autophagic flux are detected in human aortic smooth muscle cells (HASMCs) under hypoxia treatment. CCK‐8, transwell, and wound healing assay are used to identify proliferation and migration under hypoxia treatment. Furthermore, 3‐MA is used to inhibit autophagy in hypoxia‐treated HASMCs. This study reveals that AD tissues highly express HIF‐1α and the LC3. Autophagy is induced under hypoxia in a time‐dependent manner, and autophagy is positively related to HIF‐1α in HASMCs. Moreover, the proliferation and migration of HASMCs are enhanced by hypoxia, whereas the knockdown of HIF‐1α attenuates this effect. Additionally, inhibiting autophagy with 3‐MA ameliorates hypoxia‐induced proliferation and migration of HASMCs. In summary, the above results indicate that HIF‐1α facilitates HASMC proliferation and migration by upregulating autophagy in a hypoxic microenvironment. Thus, inhibition of autophagy may be a novel therapeutic target for the prevention and treatment of AD.
12 December 2025 in American Journal of Preventive Cardiology
Ischemic heart disease (IHD) remains the leading cause of global mortality. Apart from traditional risk factors like hypertension and dyslipidemia, ambient temperature extremes—both cold and heat—have increasingly been recognized as important but underexplored contributors to IHD burden, with the impact of climate change necessitating a deeper understanding of temperature-related cardiovascular risks. Here we performed a cross-sectional analysis of Global Burden of Disease 2021 data stratified by region, sex, age, and Socio-Demographic Index (SDI) aiming to demonstrating the burden of temperature extremes-related IHD. Temporal trends were quantified using estimated annual percentage change (EAPC), inequalities were assessed via the slope index and concentration index, and autoregressive integrated moving average models were used to project burden through 2050. In 2021, cold-related IHD accounted for 505,300 deaths and 9.96 million disability-adjusted life years (DALYs) worldwide. Cold-related mortality and DALYs declined since 1990 (EAPC = −1.73), whereas heat-related IHD—although smaller in absolute terms—rose over time (EAPC = 1.68). High-SDI regions experienced the largest reductions in cold-related IHD, while low-SDI regions exhibited the steepest increases in heat-related burden. Age- and sex-specific patterns differed: in males both cold- and heat-related burdens peaked at 60–69 years; in females cold-related burden peaked at 80–84 years and heat-related burden at 65–69 years. Projections suggest a continued decline in cold-related IHD but a rising heat-related burden. These findings underscore the need for climate-sensitive public health strategies to mitigate temperature-related cardiovascular risk, particularly in less developed regions.
To compare the safety and efficacy of indobufen-based versus aspirin-based sequential antiplatelet therapy in septuagenarians undergoing coronary artery bypass grafting (CABG). Patients aged 70–79 years who underwent CABG between 2020 and 2022 received either indobufen- or aspirin-based dual antiplatelet therapy (DAPT) (with clopidogrel) for 12 months, followed by monotherapy with their respective baseline agent (indobufen or aspirin) for an additional year. Propensity score matching (1:2, caliper 0.25 SD) balanced the baseline characteristics. The primary outcomes were 2-year major adverse cardiac and cerebrovascular events (MACCE) and Bleeding Academic Research Consortium (BARC) types 2, 3, or 5 bleeding. Among 296 patients (indobufen, 46; aspirin, 250), 104 (indobufen, 36; aspirin, 68) were well matched. Before matching, indobufen showed similar 2-year MACCE risk to aspirin (6.5% vs 6.8%; subdistribution hazard ratio [sHR] 0.96, 95% CI 0.28–3.28; p = 0.95) and lower BARC type 2, 3, or 5 bleeding (2.2% vs 6.8%; sHR 0.32, 95% CI 0.04–2.38; p = 0.23). After matching, results remained consistent (MACCE 8.3% vs 10.3%; sHR 0.81, 95% CI 0.21–3.10; p = 0.76; bleeding 2.8% vs 11.8%; sHR 0.24, 95% CI 0.03–1.87; p = 0.14). Indobufen reduced clinically relevant bleeding by 9.0% (number needed to treat [NNT] ≈ 11) without compromising ischemic outcomes. Indobufen-based sequential therapy provided ischemic protection similar to that of aspirin, while showing a favorable bleeding profile in septuagenarians undergoing CABG. For individuals with a high bleeding risk or aspirin intolerance, indobufen may represent a practical alternative. Larger prospective studies focusing on geriatric outcomes are warranted.
Background: Serotonin, as an important neurotransmitter and signaling molecule, can affect thoracic aortic aneurysm (TAA) by regulating vascular cell proliferation, angiogenesis, and immune status. This research aimed to conduct a comprehensive analysis to pinpoint serotonin-related biomarkers in TAA and to elucidate their potential molecular mechanisms. Methods: Biomarkers were selected and validated through differential expression analysis, weighted gene co-expression network analysis (WGCNA), machine learning algorithms, and expression verification. Moreover, the constructed nomogram, enrichment analysis, immune infiltration analysis, and compound prediction validated the regulatory roles of the biomarkers in TAA. The single-cell dataset was analyzed to determine key cells and perform pseudo-time analysis. Simulated knockout of biomarkers was performed to determine their underlying functions and related pathways. Finally, reverse transcription quantitative PCR (RT-qPCR) was employed to confirm the expression levels of the biomarkers. Results: Overall, two biomarkers (CD300A and CLU) were determined to be associated with serotonin in TAA. The nomogram showed good performance in predicting TAA risk. These biomarkers were significantly enriched in the hematopoietic cell lineage and natural killer (NK) cell mediated cytotoxicity. Biomarker expression was significantly correlated with the infiltration proportions of M2 macrophages and neutrophils. The biomarkers were stably bound to tetrachlorodibenzodioxin and bisphenol A. Moreover, pseudo-time analysis demonstrated a notable correlation between biomarker expression and the differentiation status of monocytes/macrophages/dendritic cells (MonoMac/DC). Genes perturbed by knockout were enriched in the pyrimidine metabolism and RIG-I-like receptor signaling pathway. Finally, RT-qPCR validated that CLU was downregulated and CD300A was upregulated in the TAA group. Conclusions: Biomarkers (CD300A and CLU) associated with serotonin in TAA were identified, with their expression trends validated by RT-qPCR. This work provides novel bioinformatic insights, and direct functional experiments are required to support future therapeutic development for TAA.